Sucralfate in the treatment of duodenal ulcers: a double-blind endoscopically controlled trial.
This trend was maintained at 12 weeks (on sulcralfate 77% complete healing and 7% partial healing, on placebo 44% complete healing and 15% partial healing; chi 2 score 4,9402; P < 0,05). No statistically significant difference was achieved at 6 or 12 weeks for small ulcers. At 6 weeks, 73% of large ulcers were completely healed and 18% were partially healed compared with 21% on placebo completely and 43% partially healed (Fisher's exact P value of 0,092 in favour of sucralfate). No differences were found at 12 weeks. No side-effects were noted. Measurement of kaolin partial thromboplastin time and single-stage prothrombin time as measurement of heparin-like activity showed no differences before and after therapy. It is concluded that sucralfate is a safe and effective therapy for duodenal ulceration.
D000328:Adult; D000535:Aluminum / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013392:Sucralfate; D013395:Sucrose / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013392:Sucralfate; D013395:Sucrose; D000535:Aluminum